bluuebunny/crossref_metadata_2025_split huggingface dataset:
The progressive nature of Wallerian degeneration in wild-type and slow Wallerian degeneration (WldS) nerves
Authors: Beirowski Bogdan , Adalbert Robert , Wagner Diana , Grumme Daniela S , Addicks Klaus , Ribchester Richard R , Coleman Michael P 
Published: February 2005

Abstract
Background
The progressive nature of Wallerian degeneration has long been controversial. Conflicting reports that distal stumps of injured axons degenerate anterogradely, retrogradely, or simultaneously are based on statistical observations at discontinuous locations within the nerve, without observing any single axon at two distant points. As axon degeneration is asynchronous, there are clear advantages to longitudinal studies of individual degenerating axons. We recently validated the study of Wallerian degeneration using yellow fluorescent protein (YFP) in a small, representative population of axons, which greatly improves longitudinal imaging. Here, we apply this method to study the progressive nature of Wallerian degeneration in both wild-type and slow Wallerian degeneration (WldS) mutant mice.

Results
In wild-type nerves, we directly observed partially fragmented axons (average 5.3%) among a majority of fully intact or degenerated axons 37–42 h after transection and 40–44 h after crush injury. Axons exist in this state only transiently, probably for less than one hour. Surprisingly, axons degenerated anterogradely after transection but retrogradely after a crush, but in both cases a sharp boundary separated intact and fragmented regions of individual axons, indicating that Wallerian degeneration progresses as a wave sequentially affecting adjacent regions of the axon. In contrast, most or all WldS axons were partially fragmented 15–25 days after nerve lesion, WldS axons degenerated anterogradely independent of lesion type, and signs of degeneration increased gradually along the nerve instead of abruptly. Furthermore, the first signs of degeneration were short constrictions, not complete breaks.

Conclusions
We conclude that Wallerian degeneration progresses rapidly along individual wild-type axons after a heterogeneous latent phase. The speed of progression and its ability to travel in either direction challenges earlier models in which clearance of trophic or regulatory factors by axonal transport triggers degeneration. WldS axons, once they finally degenerate, do so by a fundamentally different mechanism, indicated by differences in the rate, direction and abruptness of progression, and by different early morphological signs of degeneration. These observations suggest that WldS axons undergo a slow anterograde decay as axonal components are gradually depleted, and do not simply follow the degeneration pathway of wild-type axons at a slower rate.
The effects of long-term total parenteral nutrition on gut mucosal immunity in children with short bowel syndrome: a systematic review
Authors: Duran Beyhan 
Published: February 2005

Abstract
Background
Short bowel syndrome (SBS) is defined as the malabsorptive state that often follows massive resection of the small intestine. Most cases originate in the newborn period and result from congenital anomalies. It is associated with a high morbidity, is potentially lethal and often requires months, sometimes years, in the hospital and home on total parenteral nutrition (TPN). Long-term survival without parenteral nutrition depends upon establishing enteral nutrition and the process of intestinal adaptation through which the remaining small bowel gradually increases its absorptive capacity. The purpose of this article is to perform a descriptive systematic review of the published articles on the effects of TPN on the intestinal immune system investigating whether long-term TPN induces bacterial translocation, decreases secretory immunoglobulin A (S-IgA), impairs intestinal immunity, and changes mucosal architecture in children with SBS.

Methods
The databases of OVID, such as MEDLINE and CINAHL, Cochran Library, and Evidence-Based Medicine were searched for articles published from 1990 to 2001. Search terms were total parenteral nutrition, children, bacterial translocation, small bowel syndrome, short gut syndrome, intestinal immunity, gut permeability, sepsis, hyperglycemia, immunonutrition, glutamine, enteral tube feeding, and systematic reviews. The goal was to include all clinical studies conducted in children directly addressing the effects of TPN on gut immunity.

Results
A total of 13 studies were identified. These 13 studies included a total of 414 infants and children between the ages approximately 4 months to 17 years old, and 16 healthy adults as controls; and they varied in design and were conducted in several disciplines. The results were integrated into common themes. Five themes were identified: 1) sepsis, 2) impaired immune functions: In vitro studies, 3) mortality, 4) villous atrophy, 5) duration of dependency on TPN after bowel resection.

Conclusion
Based on this exhaustive literature review, there is no direct evidence suggesting that TPN promotes bacterial overgrowth, impairs neutrophil functions, inhibits blood's bactericidal effect, causes villous atrophy, or causes to death in human model.
The hypothesis relating negative effects of TPN on gut immunity remains attractive, but unproven. Enteral nutrition is cheaper, but no safer than TPN. Based on the current evidence, TPN seems to be safe and a life saving solution.
Are ICD-10 codes appropriate for performance assessment in asthma and COPD in general practice? Results of a cross sectional observational study
Authors: Schneider Antonius , Gantner Lutz , Maag Inko , Borst Mathias M , Wensing Michel , Szecsenyi Joachim 
Published: February 2005

Abstract
Background
The increasing prevalence and impact of obstructive lung diseases and new insights, reflected in clinical guidelines, have led to concerns about the diagnosis and therapy of asthma and COPD in primary care. In Germany diagnoses written in medical records are used for reimbursement, which may influence physicians' documentation behaviour. For that reason it is unclear to what respect ICD-10 codes reflect the real problems of the patients in general practice. The aim of this study was to assess the appropriateness of the recorded diagnoses and to determine what diagnostic information is used to guide medical treatment.

Methods
All patients with lower airway symptoms (n = 857) who had attended six general practices between January and June 2003 were included into this cross sectional observational study. Patients were selected from the computerised medical record systems, focusing on ICD-10-codes concerning lower airway diseases (J20-J22, J40-J47, J98 and R05). The performed diagnostic procedures and actual medication for each identified patient were extracted manually. Then we examined the associations between recorded diagnoses, diagnostic procedures and prescribed treatment for asthma and COPD in general practice.

Results
Spirometry was used in 30% of the patients with a recorded diagnosis of asthma and in 58% of the patients with a recorded diagnosis of COPD. Logistic regression analysis showed an improved use of spirometry when inhaled corticosteroids were prescribed for asthma (OR = 5.2; CI 2.9–9.2) or COPD (OR = 4.7; CI 2.0–10.6). Spirometry was also used more often when sympathomimetics were prescribed (asthma: OR = 2.3; CI 1.2–4.2; COPD: OR = 4.1; CI 1.8–9.4).

Conclusions
This study revealed that spirometry was used more often when corticosteroids or sympathomimetics were prescribed. The findings suggest that treatment was based on diagnostic test results rather than on recorded diagnoses. The documented ICD-10 codes may not always reflect the real status of the patients. Thus medical care for asthma and COPD in general practice may be better than initially found on the basis of recorded diagnoses, although further improvement of practice patterns in asthma and COPD is still necessary.
Morning versus evening dosing of desloratadine in seasonal allergic rhinitis: a randomized controlled study [ISRCTN23032971].
Authors: Haye Rolf , Høye Kjetil , Berg Olof , Frønes Sissel , Ødegård Tone 
Published: February 2005

Abstract
Background
A circadian rhythm of symptoms has been reported in allergic rhinitis and some studies have shown the dosing time of antihistamines to be of importance for optimizing symptom relief in this disease. The objective of this study was to examine the efficacy of morning vs. evening dosing of the antihistamine desloratadine at different time points during the day.

Methods
Patients ≥ 18 years, with seasonal allergic rhinitis received desloratadine 5 mg orally once daily in the morning (AM-group) or evening (PM-group) for two weeks. Rhinorrhea, nasal congestion, sneezing and eye symptoms were scored morning and evening. Wilcoxon rank sum and 2-way ANOVA test were used.

Results
Six-hundred and sixty-three patients were randomized; 336 in the AM-group; 327 in the PM-group. No statistically significant differences were seen between the AM and PM group at any time points. In the sub-groups with higher morning or evening total symptom score no difference in treatment efficacy was seen whether the dose was taken 12 or 24 hours before the higher score time. There was a circadian variation in baseline total symptom score; highest during daytime and lowest at night. The circadian variation in symptoms was reduced during treatment. This reduction was highest for daytime symptoms.

Conclusions
A circadian rhythm was seen for most symptoms being more pronounced during daytime. This was less apparent after treatment with desloratadine. No statistically significant difference in efficacy was seen whether desloratadine was given in the morning or in the evening. This gives the patients more flexibility in choosing dosing time.
Genomic analysis of early murine mammary gland development using novel probe-level algorithms
Authors: Master Stephen R , Stoddard Alexander J , Bailey L Charles , Pan Tien-Chi , Dugan Katherine D , Chodosh Lewis A 
Published: February 2005

AbstractWe describe a novel algorithm (ChipStat) for detecting gene-expression changes utilizing probe-level comparisons of replicate Affymetrix oligonucleotide microarray data. A combined detection approach is shown to yield greater sensitivity than a number of widely used methodologies including SAM, dChip and logit-T. Using this approach, we identify alterations in functional pathways during murine neonatal-pubertal mammary development that include the coordinate upregulation of major urinary proteins and the downregulation of loci exhibiting reciprocal imprinting.
Septicemia in the First Week of Life in a Norwegian National Cohort of Extremely Premature Infants
Authors: Rønnestad Arild , Abrahamsen Tore G. , Medbø Sverre , Reigstad Hallvard , Lossius Kristin , Kaaresen Per I. , Engelund Inger E. , Irgens Lorentz M. , Markestad Trond 
Published: February 2005

Objectives. To investigate the incidence, causes, predictors, and outcomes of septicemia in the first week of life in a national cohort of extremely premature infants.
Methods. A prospective study of survival of all infants with gestational age of &lt;28 weeks or birth weight of &lt;1000 g who were born in Norway in 1999–2000 was performed. Data on the maternal prenatal history, delivery, and neonatal course, including detailed information on episodes of microbiologically verified septicemia, were collected on predefined forms. Septicemia was reported in 2 groups, ie, episodes diagnosed on the day of delivery (ie, very early-onset septicemia [VEOS]) and episodes diagnosed from day 2 to day 7 of life (ie, early-onset septicemia [EOS]). Logistic regression models were used for the selection of variables for predictor analysis in each group.
Results. Of 462 included infants, VEOS occurred for 15 (32.5 per 1000 population) and EOS for 15 (35.5 per 1000 population). The most prevalent bacteria were Escherichia coli in VEOS (n = 9) and staphylococci (coagulase-negative staphylococci and Staphylococcus aureus) (n = 15) in EOS. Case fatality rates were 40% and 13%, respectively. Independent predictive factors for VEOS were clinical chorioamnionitis (odds ratio [OR]: 10.5; 95% confidence interval [CI]: 3.3-33.4) and high maternal age (OR: 1.2; 95% CI: 1.0–1.3), whereas not receiving systemic antibiotic therapy within 2 days of age (OR: 13.6; 95% CI: 3.7–50.2) and receiving nasal continuous positive airway pressure (n-CPAP) support at 24 hours of age (OR: 9.8; 95% CI: 2.5–38.4) independently predicted septicemia after the first day of life.
Conclusions. Whereas vertically transmitted septicemia was dominated by Gram-negative bacteria, with predictors being exclusively of maternal origin, EOS was dominated by typically nosocomial flora, with n-CPAP treatment at 24 hours of age being a powerful predictor. Early n-CPAP treatment, as opposed to mechanical ventilation, as a powerful predictor of septicemia in the early neonatal period, even with adjustment for early systemic antibiotic treatment, is a new observation among extremely premature infants that warrants additional study.
Utility of Rapid B-Type Natriuretic Peptide Assay for Diagnosis of Symptomatic Patent Ductus Arteriosus in Preterm Infants
Authors: Choi Byung Min , Lee Kee Hyoung , Eun Baik Lin , Yoo Kee Hwan , Hong Young Sook , Son Chang Sung , Lee Joo Won 
Published: February 2005

Objective. In preterm infants, the rapid and accurate determination of the presence of a hemodynamically significant patent ductus arteriosus (PDA) is extremely important, but this is often difficult. Plasma B-type natriuretic peptide (BNP) measurement has been reported to be a helpful aid in the diagnosis of hemodynamically significant PDA in preterm infants. The aim of our study was to investigate the usefulness of a rapid BNP assay as a diagnostic marker of symptomatic PDA (sPDA) in preterm infants.
Methods. Sixty-six preterm infants, ranging from 25 to 34 gestational weeks of age, underwent clinical and echocardiographic examinations for PDA every other day from the third day of life until the disappearance of ductal flow. Blood samples were collected and plasma BNP concentrations were measured simultaneously using a commercial kit, (Triage BNP test kit; Biosite Diagnositics, San Diego, CA). When ≥2 clinically significant features of PDA were noted, and a large ductal flow was confirmed by color Doppler echocardiography, sPDA was diagnosed and treated with indomethacin.
Results. On the third day after birth, the mean BNP concentration in the sPDA group (n = 23) was significantly higher than in the control group (n = 43) (2896 ± 1627 vs 208 ± 313 pg/mL). Seventeen infants (74%) in the sPDA group became asymptomatic after an initial course of indomethacin and their BNP levels concomitantly decreased. Moreover, BNP concentrations were significantly correlated with the magnitudes of the ductal shunt, such as the ratio of left atrial to aortic root diameter and the diastolic flow velocity of the left pulmonary artery (r = 0.726 and 0.877). The area under the receiver operator characteristic curve for the detection of sPDA was high: 0.997 (95% confidence interval: 0.991–1.004). The best cutoff of BNP concentration for the diagnosis of sPDA was determined to be 1110 pg/mL (sensitivity: 100%; specificity: 95.3%).
Conclusion. In preterm infants, the circulating BNP levels correlated well with the clinical and echocardiographic assessments of PDA. Although not a stand-alone test, the rapid BNP assay provides valuable information for the detection of infants with sPDA that require treatment. Moreover, serial BNP measurements may be of value in determining the clinical course of PDA in preterm infants.
The Influence of Bone Thickness on Facial Marginal Bone Response: Stage 1 Placement Through Stage 2 Uncovering
Authors: Spray J. Robert , Black C. Gary , Morris Harold F. , Ochi Shigeru 
Published: February 2005

Background: Various causes of facial bone loss around dental implants are reported in the literature; however, reports on the influence of residual facial bone thickness on the facial bone response (loss or gain) have not been published. This study measured changes in vertical dimension of facial bone between implant insertion and uncovering and compared these changes to facial bone thickness for more than 3,000 hydroxyapatite (HA)‐coated and non–HA‐coated root‐form dental implants.Methods: Subjects were predominantly white males, 18 to 80+ years of age (mean 62.9 years), who were patients at 30 Department of Veterans Affairs Medical Centers and two university dental clinics. Alveolar ridges ranged from normal to resorbed with intact basal bone. Following preparation of the osteotomy site, direct measurements with calipers were made of the residual facial bone thickness, approximately 0.5 mm below the crest of the bone. The distance from the top of the implants to the crest of the facial bone was also measured using periodontal probes. Implants were uncovered between 3 to 4 months in the mandible and 6 to 8 months in the maxilla after insertion. Facial bone response was the difference between the height of facial bone at Stage 1 (insertion) and Stage 2 (uncovering).Results:The mean facial bone thickness after osteotomies were made was 1.7 ± 1.13 mm. When a mean facial bone thickness of 1.8 ± 1.41 mm or larger remained after site preparation, bone apposition was more likely to occur. The mean facial bone response for 2,685 implants was −0.7 ± 1.70 mm. For implants integrated at uncovering, the mean bone response was −0.7 ± 1.69 mm, and −2.8 ± 1.57 mm for implants mobile at uncovering. Bone quality‐4 had the least facial bone response, −0.5 ± 2.11 mm. Bone responses were similar for both HA‐coated and non—HA‐coated implants.Conclusions: Significantly greater amounts of facial bone loss were associated with implants that failed to integrate. As the bone thickness approached 1.8 to 2 mm, bone loss decreased significantly and some evidence of bone gain was seen. There was no statistically or clinically significant difference in bone response between HA‐coated and non—HA‐coated implants. Ann Periodontol 2000;5:119‐128.
Survival and Stability (PTVs) of Six Implant Designs From Placement to 36 Months
Authors: Morris Harold F. , Ochi Shigeru 
Published: February 2005

Background: Numerous new implant designs and materials have become available over the last decade, each with special claims of superiority in restoring complex cases. Differences in existing clinical databases, study designs, and methods of determining failures/survival are seldom standardized, which complicates comparisons of clinical performance of these new designs. Little information is available concerning the changes in stability of various designs and materials following clinical loading.Methods: A total of 30 VA medical centers and 2 dental schools combined to form the Dental Implant Clinical Research Group (DICRG). More than 2,900 implants were placed, restored and data gathered from the time of placement to 36 months. Implant stability from uncovering to 36 months and survival from placement to 36 months were determined. Survival was determined using two different approaches—considering all implants removed at any time, regardless of the reason (DICRG approach), and considering only those that were removed following loading of the prosthesis (post‐loading approach). Survival was also determined for each of the three phases of implant treatment—phase 1, from the time of placement to uncovering and abutment connection; phase 2, from uncovering to placement and loading of the prosthesis; and phase 3, from loading of the prosthesis to 36 months.Results: The two approaches to determining survival for each implant design and/or material included in the study showed differences in reported numbers ranging from 1.1% to 21.7%. The largest difference in survival was for the commerically pure titanium screw (used in this study only in the maxillary completely edentulous applications), which showed a 21.7% greater survival rate. With the DICRG approach, the hydroxyapatite (HA)‐cylinder had the highest survival (97.5%). When considering the post‐loading approach, the titanium‐alloy screw had the highest survival (99.4%), with the HA‐cylinder having the next highest survival (98.6%). The HA‐cylinder did not show increased stability from uncovering to 36 months, and the HA‐grooved implant became less stable.Conclusions: HA‐coated implants demonstrated the highest survival rate; 2) the post‐loading analysis approach inflated survival; 3) non‐HA implants showed increased stability following loading; 4) HA‐coated implants showed a slight decrease or no change in stability; and 5) the clinical significance of the changes in implant stability must be determined for the long term. Ann Periodontol 2000;5:15‐21.
Implant Survival to 36 Months as Related to Length and Diameter
Authors: Winkler Sheldon , Morris Harold F. , Ochi Shigeru 
Published: February 2005

Background: It is generally accepted that diameter and length of an endosseous dental implant and its stability at placement are critical factors in achieving and maintaining osseointegration. In the event of slight implant mobility at placement, the conventional or accepted treatment is to place a longer implant and/or one of wider diameter. This manuscript presents stability and survival/failure data for implants of different diameters and lengths following 36 months post‐placement, as well as crestal bone loss data between placement and uncovering.Methods: A subset of the Dental Implant Clinical Research Group's database was used to study the 3‐ year survival and stability of various implant lengths (7 mm, 8 mm, 10 mm, 13 mm, and 16 mm) and diameters (3 mm+ and 4 mm+). Placement to uncovering crestal bone loss was also determined. The implants were generally representative of those available for clinical use (screws, basket, grooved, hydroxy‐apatitecoated, CP‐Ti, Ti‐alloy). The study protocol specified that the implants be randomized to various jaw regions to accomplish the primary goals of the study—the comparison of each implant design's overall survival. A total of 2,917 implants were placed, restored, and followed. Data for all 3 mm to 3.9 mm diameter implants were pooled into a “3+” group, and the 4 mm to 4.9 mm diameter implants into a “4+” mm group. No attempt was made to look at the influence of any other variables on survival outcomes. The possible influence of clustering on survival was taken into consideration.Results: The 3+ mm group had a mean stability (PTV) of −3.8 (SD = 2.9), and the 4+ group had a mean PTV of −4.4 (SD = 2.7) (P <0.05). The PTVs for implant lengths ranged from −2.9 (SD = 2.8) for 7 mm lengths to −3.9 (SD = 2.9) for 16 mm lengths (P <0.05). Survival to 36 months was 90.7% for the 3+ diameter and 94.6% for the 4+ group (P = 0.01). Survival ranged from 66.7% for the 7 mm implants to 96.4% for 16 mm implants (P = 0.001). Outcomes did not change when clustering was considered, although the P value decreased slightly.Conclusions: The results indicate that: 1) shorter implants had statistically lower survival rates as compared with longer implants; 2) 3+ mm diameter implants had a lower survival rate as compared with 4+ mm implants; 3) 3+ mm diameter implants are less stable (more positive PTVs) than 4+ mm implants; and 4) there was no significant difference in crestal bone loss for the two different implant diameters between placement and uncovering.Ann Periodontol 2000;5:22‐31.